US-listed Chinese biopharma firm Gracell to raise $150m in Vivo Capital-led PIPE deal

US-listed Chinese biopharma firm Gracell to raise $150m in Vivo Capital-led PIPE deal

Laboratory equipment. Photo: Pixabay

Eudora Wang

09 August, 2023

Edited by: Pramod Mathew

autoimmune diseasesbiopharmaceuticalcell therapiesGracell Biotechnologiesprivate placementVivo Capital

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter

You may also like

Read more from Greater China

Nikkei Logo
DealStreetAsia Logo
About Us
Team
Advertise
Contact
Careers
Blog
Privacy Policy
Terms & Conditions
© Copyright DEALSTREETASIA 2014-2025 All rights reserved.